Peptides Take Center Stage at FDA’s Critical Stakeholder Meeting

Key Takeaways: The FDA’s Pharmacy Compounding Advisory Committee meeting later this month will evaluate whether seven peptides should be eligible for compounding under Section 503A. Strong support from PCAC may signal future change in the FDA’s policies regarding the compounding of some or all of these peptides.... By: Polsinelli